Q3 EPS Forecast for Abeona Therapeutics Increased by Analyst

Abeona Therapeutics Inc (NASDAQ:ABEO) – Investment analysts at Zacks Small Cap lifted their Q3 2025 EPS estimates for shares of Abeona Therapeutics in a report issued on Wednesday, April 30th. Zacks Small Cap analyst D. Bautz now anticipates that the biopharmaceutical company will post earnings of ($0.18) per share for the quarter, up from their previous estimate of ($0.34). The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. Zacks Small Cap also issued estimates for Abeona Therapeutics’ Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.74) EPS, FY2026 earnings at $0.87 EPS and FY2027 earnings at $2.15 EPS.

Several other brokerages have also recently commented on ABEO. Oppenheimer started coverage on shares of Abeona Therapeutics in a report on Wednesday, March 5th. They set an “outperform” rating and a $16.00 target price for the company. HC Wainwright raised their price objective on Abeona Therapeutics from $15.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday. Finally, StockNews.com upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, March 24th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $18.75.

Abeona Therapeutics Trading Down 4.5 %

NASDAQ:ABEO opened at $6.56 on Friday. The company has a market cap of $320.13 million, a P/E ratio of -2.44 and a beta of 1.68. Abeona Therapeutics has a twelve month low of $3.93 and a twelve month high of $7.32. The business has a 50 day moving average price of $5.09 and a two-hundred day moving average price of $5.61. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.19.

Insider Transactions at Abeona Therapeutics

In related news, CEO Vishwas Seshadri sold 25,000 shares of the stock in a transaction on Monday, March 31st. The stock was sold at an average price of $4.78, for a total value of $119,500.00. Following the sale, the chief executive officer now owns 1,355,322 shares in the company, valued at approximately $6,478,439.16. This represents a 1.81 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 5.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Abeona Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Twinbeech Capital LP bought a new stake in shares of Abeona Therapeutics during the 4th quarter worth about $58,000. Northern Trust Corp boosted its holdings in shares of Abeona Therapeutics by 6.6% during the fourth quarter. Northern Trust Corp now owns 184,929 shares of the biopharmaceutical company’s stock worth $1,030,000 after acquiring an additional 11,478 shares during the period. Squarepoint Ops LLC bought a new stake in shares of Abeona Therapeutics during the fourth quarter worth approximately $67,000. Jane Street Group LLC bought a new position in shares of Abeona Therapeutics during the third quarter worth approximately $84,000. Finally, Cannon Global Investment Management LLC acquired a new stake in Abeona Therapeutics during the 1st quarter worth approximately $67,000. 80.56% of the stock is currently owned by institutional investors and hedge funds.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.